Group items tagged

Digestive issues such as constipation, dysphagia and irritable bowel syndrome (IBS) may be precursors of Parkinson's disease, according to research published in the journal Gut. Gastrointestinal symptoms are thought to precede the development of some cerebrovascular disease, including brain aneurysm or Alzheimer's disease, and it has been suggested (Braak's hypothesis) that gut conditions may precede the development of Parkinson's disease too. To test this hypothesis, researchers used data from a US nationwide medical record network (TriNetX) to compare 24,624 people who had been diagnosed with Parkinson's disease of unknown cause with those who had been diagnosed with other neurological conditions - Alzheimer's disease (19,046) or cerebrovascular disease (23,942) - or with none of these (24,624; comparison group).

According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. This figure will nearly double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The WHO Global Status Report for 2021 estimated the yearly global cost of dementia to be more than USD 1.3 trillion, with a projected increase to USD 2.8 trillion by 2030. To date most drugs developed to treat Alzheimer's disease have failed, largely because they target wrong biomarkers and individuals already exhibiting signs of the disease. Once symptoms appear, however, many brain cells responsible for memory and cognition are likely already damaged and beyond repair. Professor Shai Rahimipour in the Chemistry Department at Bar-Ilan University in Israel has pioneered a different approach utilizing theranostics to pinpoint and treat the earliest, pre-symptomatic signs of Alzheimer's disease. Showing promise in stopping progression of the disease before onset of irreversible brain cell damage, Rahimipour's groundbreaking approach has garnered significant attention in the scientific world.

Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company dedicated to developing novel treatments for rare diseases. More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still have no approved treatment. The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp, Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development." Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a positive impact on patients living with rare diseases." With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.

Gum disease alone is a potential indicator of multiple severe heart conditions such as coronary artery disease. A recent study by AGD confirmed a correlation between gum disease and heart disease.

Cardiovascular diseases (CVDs) are the types of diseases that affect heart and blood vessels, causing heart attacks, stroke, congenital heart disease, and peripheral artery disease. Tobacco use, unhealthy diet, alcohol, and physical inactivity trigger CVDs. Here's all you need to know about CVDs.

British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan. AbbVie will stop funding the drug's development, AstraZeneca said. AbbVie's Skyrizi also treats Crohn's disease.

Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. This more serious form of nonalcoholic fatty liver disease is sometimes called nonalcoholic steatohepatitis. At its most severe, nonalcoholic fatty liver disease can progress to liver failure.

This means to stay we have to stay away from food and drinks that may damage our liver. Thanks for the info!

a must read especially for everyone!

A cancer registry is the cancer cases which are registered in a population or specific country. In whole world mortality rate due to cancer is 20%. In USA cancer is the second largest disease of causing death after heart disease. Recently in 2016 estimated that 595,690 people die from this disease according to cancer statistics of National Cancer Institute USA.

The National Institute for Health and Care Excellence (NICE) today issued a draft guidance recommending dapagliflozin, sold under the brand name Forxiga among others, as an option for treating certain adults with chronic kidney disease (CKD). Dapagliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE's technology appraisal process for CKD. Adding dapagliflozin to current standard care has been shown to significantly reduce the risk of having declining kidney function, end-stage kidney disease, or dying from causes related to the kidneys or cardiovascular system. "Dapagliflozin is a promising treatment for certain people with chronic kidney disease and it has the potential to increase the length of time before the disease gets worse," Meindert Boysen, deputy chief executive and director of the NICE Centre for Health Technology Evaluation, said.

Heart surgery is a major medical procedure that is often performed to treat heart diseases and conditions. Heart disease umbrella consists of disease like congenital coronary heart defects, arrhythmias & blood vessel diseases like coronary artery disease.

Diabetes drugs that also promote weight loss such as Novo Nordisk's Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer's disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose utilisation and tamping down inflammation in the entire body - including the brain - could slow progression of debilitating diseases like Alzheimer's and Parkinson's. Several scientists interviewed by Reuters news agency pointed to mounting research supporting testing diabetes drugs against neurodegenerative diseases. Results are years away and success uncertain. But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai with partner Biogen and by Eli Lilly demonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs.

Benefits of Echinacea for Health and Wellness The Echinacea plant is still in benefit today as a dietary supplement. It has nine species, but only two of them, Echinacea purpurea and Echinacea angustifolia are generally used in supplements. Other supplements are in pill form, teas, juices, and creams. It possesses many compounds that may benefit your health. 1/10_ It treat infections and wounds Echinacea has been used for centuries to treat infections and wounds. In fact, the Native Americans used echinacea to treat their cuts, burns, bruises, and insect bites. They'd apply the fresh plant directly onto their skin to heal those wounds faster than they would have otherwise. It has also been shown in multiple studies to be effective in treating colds and other infections. This benefit is believed to be due to its immune-boosting properties that help strengthen your body's defenses against bacteria. ECZEMA People with eczema suffer from an inflammation of the skin; a cream including echinacea extract may benefit. Early research suggests that daily topical application of echinacea cream helped alleviate eczema-related irritation. It also helped create the protective outer layer of skin. Be aware of probable allergic reactions, as people with eczema generally have allergies and asthma. 2/10_Antioxidant powerhouse Antioxidants are substances that protect you from disease by neutralizing or eliminating the damaging effects of free radicals. Free radicals are atoms, molecules, or ions in your body that have an unpaired electron and can cause oxidative stress in your cells. Echinacea is a powerful antioxidant that helps fight the free radicals that cause damage to cells and tissues. Free radicals may contribute to cancer development, cardiovascular disease, arthritis, diabetes mellitus, Alzheimer's disease, and many other chronic diseases. Echinacea has been shown in studies to positively impact the immune system by boosting its response against infection-causing

Sugar and heart disease has a big link. You do not have to be diabetic to watch your sugar intake. Sugar is a cause of inflammation. Sugar and heart disease has a big link and as I have talked about in the past. Don't just look for the heart health check mark on foods as these foods have given money to these heart health organizations that can lead into a viscous cycle

What Is Leprosy Disease? Leprosy is a chronic, granulomatous infection caused by the... According to historical records, this disease spread through the slave trade and migration routes from... In this article, we talk about the causes, symptoms, and treatment of Leprosy

Like TB, leprosy is caused by a bacterium. The bacterium is Mycobacterium Leprae. It was discovered by Armauer Hansen in Norway in 1873. This is why it is also called Hansen's disease. Although its bacterial nature was known at the time, it was not considered infectious.

Arrowhead Pharmaceuticals on Monday (November 22) entered a drug development deal with GlaxoSmithKline (GSK) under which the British drugmaker will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH. Under the pact, Arrowhead said it would get an upfront payment of $120 million and is eligible for additional milestone payments including up to $190 million at first commercial sale of the product, and up to $590 million in sales-related milestone payments. The drug candidate, ARO-HSD, is currently in an early-to-mid stage trial for nonalcoholic steatohepatitis (NASH), a fatty liver disease. It is based on RNA interference technology, where genes that contribute to disease are silenced.

Super foods not only fulfill your nutrient's requirements, but they are also helpful in curing different diseases. Obesity is a common problem now days, at present it is also termed as a disease; super foods have a solution to get healthy weight loss. Furthermore, old-age disease arthritis has also a cure in super foods. Make a visit to acaifood.com for more advantages of super foods.

Pompe Disease - Pipeline Review, H1 2012', provides an overview of the Pompe Disease therapeutic pipeline. This report provides information on the therapeutic development for Pompe Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pompe Disease. 'Pompe Disease - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

This is a very long newsletter. I will answer questions about oil versus water-soluble Vitamin D, depression, mental clarity, malignant melanoma, Crohn's disease, an imagist poet, multiple sclerosis, sun-exposure, high-intensity red light and collagen repair in the skin, non-alcoholic fatty liver disease, influenza, the 1918 influenza pandemic, statins, the new Food and Nutrition Board, thyroid disease, chronic fatigue syndrome, athletes, the upcoming 14th Vitamin D Workshop, prostate cancer, the wrong blood test, pregnancy, autism, Alzheimer's disease, soap and sebum, asthma, sleep, the co-factors vitamin D needs to work (all contained in spinach), and-my favorite-UVC light and Vitamin D

A flesh-eating sexually transmitted disease called Donovanosis has baffled medical science. Though it is extremely rare, the first case was reported in UK. An unidentified woman in Southport, England, was diagnosed with the disease, which is capable of destroying genital tissue. Though not rampant in the US and UK, the disease is fairly common in India, Papua, New Guinea, the Caribbean, Central Australia, etc.